SLC22A18 is one of several tumor-suppressing subtransferable fragments located in the imprinted gene domain of 11p15.5, an important tumor-suppressor gene region. Alterations in this region have been associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. SLC22A18 is imprinted, with preferential expression from the maternal allele. Mutations in SLC22A18 have been found in Wilms' tumor and lung cancer. Solute carrier family 22 member 18 may act as a transporter of organic cations, and have a role in the transport of chloroquine and quinidine-related compounds in kidney. Several alternatively spliced transcript variants encoding different isoforms have been described.
ORCTL2 Polyclonal Antibody detects endogenous levels of ORCTL2 protein.
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB: 1:500-1:2000, IF: 1:200-1:1000, ELISA: 1:10000. Not yet tested in other applications.
ORCTL2 Polyclonal Antibody product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.
Find more details at http://www.abbkine.com/product/orctl2-polyclonal-antibody-abp52087.
bio-equip.cn
中文
